Features Partner Sites Information LinkXpress
Sign In
Demo Company

Upgraded Software Enhances Confidence in Flow Cytometry for Hematology Labs

By BiotechDaily International staff writers
Posted on 20 May 2013
Print article
An innovative software solution, with cutting-edge image analysis technology for use with a specialized 5-color reagent, has been upgraded to further enhance the performance of flow cytometry in hematology laboratories.

Beckman Coulter Inc. (Pasadena, CA, USA) introduces an advanced version of the innovative “CytoDiff CXP” Autogating Software. The software is an integral part of the company’s unique HematoFlow solution1 —combining diagnostic reagent, hematology and flow cytometry hardware, and IT expertise.

The introduction of Version 2 CytoDiff CXP Autogating software is designed to provide added confidence in the use of flow cytometry in the routine hematology lab for the autovalidation of abnormal samples. Easy-to-use, the advanced Version 2 software further improves sub-population classifications. New features include greater precision in the removal of potential interference and metrics that provide a new “confidence level” on population classification. The new software simplifies the review process, making it easier to validate results with greater certainty.

HematoFlow with the CytoDiff five-color antibody cocktail and CXP Autogating Software make it possible to use the precision of flow cytometry to deliver extended white blood cell (WBC) differential results with far greater consistency than manual microscopic assessment. The CytoDiff five-color antibody cocktail uses six monoclonal antibodies to establish the differential. “HematoFlow with CytoDiff CXP Autogating Software offers enhanced performance by delivering flow cytometry expertise alongside cutting edge image analysis technology applied to each of the multiple population classifiers,” explained Dr. Josee Naegelen, hematology marketing manager, Beckman Coulter Diagnostics Global Product Management and Strategy.

“The routine use of flow cytometry for validating abnormal samples can improve workflow and turnaround time as well as providing access to additional diagnostic information for patients,” said Dr. Naegelen. “This has a significant impact on the lab, enabling it to handle increasing workloads with greater confidence.”

Laboratories are already working with Beckman Coulter to increase confidence in the routine use of flow cytometry in the hematology process for validating abnormal samples. Hospitals including University Hospital, Rennes and Bordeaux (France), Erasme University Hospital, Brussels (Belgium), and several private labs are successfully adopting this approach. They are using Beckman Coulter’s FC 500 flow cytometer and the CytoDiff reagent to establish the extended flow WBC differential, detecting and quantifying normal and abnormal population subsets.

[1] CytoDiff is not available in the United States and other geographies.

Related Links:

Beckman Coulter

Print article



view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

How Blocking TROY Signaling Slows Brain Cancer Growth

Cancer researchers have found how the low molecular weight drug propentofylline (PPF) slows the growth of the aggressive brain tumor glioblastoma multiforme (GBM). This form of brain cancer is the most... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.